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Abstract 
 
Four hundred and twenty-one adult allogeneic haematopoietic stem cell transplant (HSCT) survivors 
participated in a cross-sectional study to assess sexual dysfunction and infertility post-transplant. 
Survey instruments included the Sydney Post-Blood and Marrow Transplant (BMT) Survey, 
Functional Assessment of Cancer Treatment (FACT) – BMT, the Depression, Anxiety, Stress Scales 
(DASS 21), the Chronic Graft-versus-Host Disease (cGVHD) Activity Assessment- Patient Self Report 
(Form B), the Lee cGVHD Symptom Scale and The Post-Traumatic Growth Inventory. Most HSCT 
survivors reported sexual difficulties (51% of males; 66% of females). Men reported erectile 
dysfunction (79%) and decreased libido (616%) and women reported loss of libido (83%), painful 
intercourse (73%) and less enjoyment of sex (68%). Women also commonly reported vaginal dryness 
(73%), vaginal narrowing (34%) and vaginal irritation (26%). Woman had much higher rates of genital 
cGvHD than men (22% vs. 5%). Age and cGVHD were significantly associated with sexual dysfunction. 
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Few survivors had children following transplant (33%). However, for those of reproductive age at 
HSCT, 22% reported trying to conceive, with 103% reporting success. This study is the largest to date 
exploring sexual function in survivors of allo-HSCT. These data provides the basis for health service 
reform to better meet the needs of HSCT survivors, including evidence to support counselling and 
education both pre- and post-transplant.  
 
Keywords: allogeneic HSCT, sexual dysfunction, infertility, survivors, survey, Australia. 
 
Introduction 
 
Allogeneic haematopoietic stem cell transplantation (HSCT) is an established treatment for 
malignant and non-malignant diseases affecting both adults and children. Advances in patient and 
donor selection, management of acute toxicities and supportive care have significantly improved 
outcomes following transplant with 1-year survival rates now 80% or more for some conditions 
(Mohty & Mohty, 2011; Pasquini & Zhu, 2014). Unfortunately, many HSCT survivors experience 
significant morbidity following HSCT with late effects reducing the quality and duration of their life 
(Savani et al, 2011). Sexual dysfunction and infertility are among the most prevalent long-term 
sequelae (Mosher et al, 2009).  
 
Sexual dysfunction and infertility occurs primarily because of the adverse effect of high dose chemo-
radiotherapy, resulting in interruption of the sexual response cycle, decreased libido, erectile and 
ejaculatory dysfunction, vaginal alterations (dryness, narrowing, fibrosis), dyspareunia and infertility 
or sub-fertility due to primary ovarian failure and impaired spermatogenesis (Carter et al, 2006; 
Humphreys et al, 2007). In general, women tend to experience more sexual dysfunction than men 
(78% at 1 year compared to 50%), are more likely to experience long-term sexual dysfunction and 
are more likely to be infertile following HSCT (Marks et al, 1997; Humphreys et al, 2007; Thygesen et 
al, 2012). While successful pregnancies have occurred in survivors of HSCT, they are rare, 06% in the 
largest report on over 37 000 HSCT survivors (both allogeneic and autologous) (Salooja et al, 2001). 
With the exception of a limited number of registry studies, there is limited data on sexual 
dysfunction and infertility post-HSCT with most studies reporting small populations from single 
centres. There is no data describing the late effects in an Australian cohort of HSCT survivors. The 
aims of this cross-sectional study were to present data on the range and frequency of sexual 
dysfunction and infertility in survivors of HSCT, to address gaps in service provision and to provide 
better information to those undergoing HSCT, their families/carers and health care professionals. 
 
Methods 
 
Patients and procedures 
 
Potential participants were identified from allogeneic transplant databases of all adult allogeneic 
transplant centres in New South Wales [NSW; Australia’s most populous state ~7.5 million in 2013 
(Australian Bureau of Statistics, 2014)]. Participants were eligible if they were ≥18 years of age and 
had undergone an allogeneic HSCT between 1 January 2000 and 31 December 2012, could read and 
write English and could provide consent. Names and phone numbers were provided to the research 
team. Consenting participants were given the option to self-complete the questionnaire or complete 
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it via a phone interview with one of the researchers. A second round of telephone calls were made 
to participants who had not returned the survey within a month. All authors had access to primary 
clinical trial data. The study protocol was approved by the Northern Sydney Local Health District 
Human Research Ethics Committee (NSLHD Reference:1207-217M). 
 
Instruments 
 
The Sydney Post-BMT Study Survey (SPBS) (Appendix S1) was developed by the research team. Item 
construction was informed by a review of the literature and discussions with patients attending 
HSCT long-term follow-up clinics. It consisted of 402 questions grouped into 20 domains, including 
questions relating to fertility and sexual function. Other relevant domains included demographics, 
medical complications, specialist referrals, tests and assessments, medications and therapies, 
infections, vaccinations, complementary therapy use, cancer screening, close personal contacts, 
lifestyle, diet nutrition, occupational and relationship status following stem cell transplantation. The 
questionnaire used tick box responses, short answer questions and 5-step Likert scales measuring 
attitudes and other factors and took approximately 1 hour to complete. The questionnaire was 
piloted in clinic and phone interviews to assess face and content validity and comprehension. 
 
Associations between sexual function and fertility were explored against demographics, medical 
complications, post-transplant medical therapies, treatments and complementary therapies, 
relationship status and social determinants, including income and occupational status. The 
relationships between sexual function and fertility were further explored against a range of 
validated survey instruments that measured quality of life [Functional Assessment of Cancer Therapy 
– Bone Marrow Transplant (FACT-BMT Version 4; Cella et al, 1993; McQuellon et al, 1997)], anxiety 
stress and depression [The DASS (Depression Anxiety Stress Scales) 21] (Lovibond & Lovibond, 1996; 
Crawford & Henry, 2003; Dahm et al, 2013), chronic graft-versus-host disease (GVHD) [The Chronic 
GVHD Activity Assessment – Patient Self Report (Form B) (Pavletic et al, 2006) and The Lee Chronic 
GVHD Symptom Scale (Lee et al, 2002b)] and an assessment of life changes in response to traumatic 
events (The Post Traumatic Growth Inventory score) (Tedeschi & Calhoun, 1996; Morris et al, 2013). 
For ease of completion all instruments were combined into one booklet.  
 
For each participant, data was collected on dates of diagnosis and transplant, stage/remission status 
at transplant, conditioning, GVHD prophylaxis, stem cell source and donor type, which was 
completed by the research team. This information was used to compare HSCT clinical variables and 
the impact on sexual function and fertility in survivors. 
 
Statistical analysis 
 
Categorical responses were summarized using frequencies and percentages. Parametric continuous 
variables were summarized using means and standard deviations, and non-parametric variables 
using medians and interquartile ranges. The Pearson v2 test or Fishers Exact tests were used for 
comparative analysis of dichotomous categorical variables. Two sample comparisons of means and 
medians were determined using the independent t-test and Wilcoxon Rank Sum tests respectively; 
greater than two sample comparisons of means and medians were determined using one way 
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analysis of variance (ANOVA) and Kruskal–Wallis tests, respectively. A two-tailed P < 005 was used as 
the level of statistical significance.  
 
Statistical analysis was performed using the STATA version 12.1 statistical package (StataCorp, 
College Station, TX, USA). 
 
Results 
 
A total of 1475 allogeneic HSCT were performed in the study period. Of the 669 survivors known to 
be alive at study sampling, 583 were contactable and were sent study packs. Four hundred and 
forty-one (66% of total eligible, 76% of those contacted) returned the completed survey. Three per 
cent declined participation (Fig 1). 
 
Fig 1. Post-haematopoietic stem cell transplantation (HSCT) survey study flowchart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient characteristics  
 
Of those who completed the survey, 250 (57%) were male and 191 (43%) female. The median age of 
survey respondents was 54 years (range: 19–79). The median age at time of transplant was 49 years 
(range: 17–71). Forty per cent of survey respondents were 6 or more years post-transplant. The 
majority of patients resided in a major city (72%), were of middle/high income status (53%) and 
were in a married or defacto relationship (79%). The main indication for transplantation was acute 
leukaemia (62%). Matched siblings accounted for 57% of donors and a myeloablative conditioning  
regimen was used in 49% of transplant procedures (Table I). 
 
 
 5 
 
Table 1. Participant characteristics  
Socio-demographic    
Gender (n=441)      
Male        n(%) 
Female    n(%) 
 
250 (56.7%) 
191 (43.3%) 
Age (years) at survey (n=441)          
Median (IQR; range) 
 
54 (44,62; 19-79) 
Age (years) at transplant (n=441)   
Median (IQR; range) 
 
49 (37,56; 17-71) 
Ethnicity  (n=372) 
Caucasian, European   n(%) 
Other *                           n(%) 
 
323 (86.8%) 
49 (13.2% 
Educational status (n=335) 
University (some/completed)     n(%) 
Other                                          n(%)  
 
154 (46.2%) 
179 (53.8%) 
Post transplant income status (n=423) 
Low income $20,000-$39,999         n(%) 
Middle income $40,000-$79,999    n(%) 
High income >=$80,000                  n(%) 
  
155 (36.6%) 
123 (29.1%) 
145 (34.3%)  
Residence (n=431) 
Major City                                                              n(%) 
Other (inner regional, outer regional, remote)      n(%) 
 
311 (72.2%) 
120 (27.8%) 
Relationship status (n=436) 
Married-Defacto                                       n(%) 
Other (separated, single, divorced)          n(%) 
 
344 (79.3%) 
90 (20.7%) 
Transplant -related 
Years since transplant   (n=443)            
< 2yrs                              n(%) 
  =2 to <6 yrs                  n(%) 
  =6 to <10 yrs                n(%) 
 >=10 yrs                       n(%) 
 
58 (13.1%) 
204 (46.3%) 
117 (26.5%) 
62 (14.1%) 
Underlying diagnosis (n=425) 
Acute Leukaemia (AML/ALL)      n(%) 
Other **                                      n(%) 
 
226 (53.4%) 
197 (46.6%) 
Remission status   (n=405) 
First/Second complete remission 
Other 
 
271 (66.9%) 
134 (33.1%) 
Donor type (n=439) 
Sibling                             n(%) 
Matched Unrelated        n(%) 
Haploidentical               n(%) 
Mismatched Unrelated  n(%) 
 
250 (56.9%) 
158 (36.0%) 
10 (2.3%) 
                21 (4.8%) 
Stem Cell source(n=441) 
Bone Marrow              n(%) 
Peripheral Blood        n(%)  
Cord Blood                n(%) 
48 (10.9%) 
381 (86.4%) 
12 (2.7%) 
Conditioning Chemotherapy (n=439) 
Myeloablative 
Reduced intensity 
214 (48.7%) 
225 (51.2%) 
 
 
Resumption of sexual activity post-HSCT 
A total of 421 respondents provided information about sexuality, fertility and sexual activity post-
HSCT; 241 (96.4%) of 250 males and 178 (93.2%) of 191 females. 
 
 6 
 
One hundred and sixty-seven (69.2%) males and 122 (68.5%) females reported resumption of sexual 
activity posttransplant; 30 (12.4%) of males and 21 (11.8%) of females had not yet resumed sexual 
activity post-HSCT. The remaining 44 (18.3%) of males and 35 (19.7%) females reported being 
sexually inactive pre and post-transplant.  
 
Males who had resumed sexual activity had a median age of 52 years, compared to 58 years for 
those who had not yet resumed sexual activity post-transplant (P = 004). The median years since 
transplantation in males who had returned to sexual activity was 5 years, and was not significant 
from males who had not yet returned to sexual activity. Males who had resumed sexual activity 
showed no significant differences in relationship status, donor type, diagnosis, conditioning, 
remission status or distribution of comorbidities when compared to males who had not resumed 
sexual activity. 
Morbidity from cGVHD was significantly higher in males who had not resumed sexual activity post-
transplant. These males reported significantly higher rates of moderate and severe cGVHD 
symptoms (P = 003), significantly higher Lee Chronic GVHD scores (P = 001) and had significantly 
higher rates of immunosuppression (P = 001) and anti-infective drug use (P = 0007). Males who had 
not returned to sexual activity post-transplant had significantly lower scores on physical (P = 001), 
functional (P = 0009) and HSCT FACT subscales (P = 0003), and had significantly lower scores on 
composite FACT scores (P = 001). No significant difference was observed in the Post-Traumatic 
Growth Inventory scores for males who had resumed sexual activity (Tables II and III1). 
 
Females who had resumed sexual activity had a median age of 49 years compared to 57 years for 
those who had not resumed sexual activity (P = 0.06) and were more likely to be further out from 
their date of transplant than those who had not resumed sexual activity with a median duration of 6 
years since transplantation, compared to 3 years (P = 0.0009). Females returning to sexual activity 
were more likely to be in a married/defacto relationship, though this was not statistically significant 
(P = 0.09). In contrast to male survivors of HSCT, the self-reported severity of GVHD symptoms and 
Lee GVHD scores were not significantly different in women who had, or had not resumed sexual 
activity. Females who had returned to sexual activity had significantly higher FACT BMT subscale 
scores, but did not have any significant differences across other FACT domains or in the post-
transplant Growth Inventory scores. Females who had resumed sexual activity reported significantly 
higher rates of anxiety and/or depression (P = 0.05). The use of psychotropic medications 
(antidepressants, anxiolytics and/or sedatives) was not significantly different between the two 
groups. The underlying haematological diagnosis, conditioning regimen, donor type, medical 
comorbidity profile and medication use was not significantly different in females who had resumed 
sexual activity (Tables II and III). 
 
Sexual dysfunction 
Fifty-one per cent of males who had resumed sexual activity since their HSCT reported difficulties 
with sexual function since transplant (Table IV). The majority (77%) of sexual difficulties in males 
related to erectile dysfunction, and decreased libido was the second most common reported 
problem (62%). Pain with intercourse accounted for 9% of sexual difficulties. Of the 122 females who 
had resumed sexual activity since their HSCT, 81 (66%) reported having difficulties with sexual 
                                                          
1
 Tables 2-6 are located at the end of this document. 
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function since transplant (Table IV). Specific issues in those who had resumed sexual activity post-
transplant were compared across genders. Females had significantly less enjoyment of sex [odds 
ratio (OR) 43 95% confidence interval (CI) 22, 88 P < 00001], less sexual desire (OR 30 95% CI 14, 66 P 
= 0002) and more pain with intercourse (OR 26 95% CI 102, 713 P < 00001) when compared to their 
male counterparts. Sexual problems arising from partner issues were similar between the two 
genders. 
 
Genital pathology 
The only genital pathology reported in men was penile cGVHD, which occurred in 13 (5%) of 250 
respondents.  
Genital problems reported by sexually active females included vaginal dryness (73%), vaginal 
narrowing (34%), vaginal irritation and soreness (26%), thrush (8%), cystitis (17%) and lower back 
pain (27%). Vaginal dryness was the only symptom that was statistically significantly different 
between women who were sexually active and those who were not (OR 52 95% CI 25, 11; P < 
00001). 
 
Menstrual irregularities 
Seventy-nine (44%) of 178 females reported having menstrual cycles prior to HSCT. Fourteen (18%) 
reported a return of menstrual function post-transplant, of which seven experienced a temporary 
cessation of up to 2 years following the transplant procedure. 
 
Fertility post-HSCT 
Three hundred and ninety-three participants provided a response to questions regarding post-
transplant conception. Thirty-five of 395 respondents indicated that they had tried to conceive post-
HSCT: 21 (10%) males and 14 (8%) females. Of these 35 participants, 15 (43%) were successful (11 
males; 4 females). Females who successfully conceived were all aged less than 30 years and males 
less than 41 years at the time of transplantation (P = 008).  
 
Of the 15 successful pregnancies, 6 (40%) were the result of natural conception (two females; four 
males) and two were the result of natural conception that followed prior attempts at in vitro 
fertilization (IVF), including IVF in one male and his partner and IVF followed by implantation of a 
donor egg in one female. A total of seven successful pregnancies were the result of IVF; six (all 
males) with IVF alone and one IVF and donor egg (female). No association was found between the 
use of reproductive technologies by HSCT survivors with residential location (major city versus inner 
or outer regional) and household income. 
 
Fertility preservation pre HSCT 
Forty-seven (20%) of 233 males reported banking sperm pre-HSCT with a median age (at transplant) 
of 31 years [inter-quartile range (IQR) 24–40; range 18–51]. There were no statistically significant 
socio-demographic differences (income, residence) between males who did and did not bank sperm 
Donor type did have a significant effect on banking sperm with those who had a haplo/MUD or 
mismatched transplant being 26 times more likely to bank than those who had a matched sibling 
transplant (95% CI 128, 544; P = 0.004). Males who had a myeloablative HSCT had a threefold higher 
rate of banking sperm than those who had reduced intensity conditioning (95% CI 167, 658; P = 
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00004) though this was not signiﬁcant when adjusting for the effect of younger age for those 
receiving myeloablative conditioning [adjusted odds ratio (AOR) 0.82; 95% CI 0.32, 2.08; P = 0.67). 
 
Three hundred and sixty-one participants responded to the question of embryo banking after a cycle 
of IVF. A total of 6 (2%) reported using this technology (two males and four females). Three hundred 
and twenty-nine participants reported whether or not they had donated ovarian tissue and frozen 
eggs for storage. Overall, 7 (2%) had used this procedure (six females and one male HSCT recipient 
with his female partner). 
 
The most common reasons for young women (aged 18–29) to have not pursued fertility preservation 
pre-HSCT were they had already completed a family or were too sick to have done so. For females in 
the 30–39 years age group, 40% declined the procedure but in a significant proportion (23%) the 
reproductive intervention was not offered. In females aged 40–49, the majority declined the 
procedure, though 15% reported that it had not been offered. Of male HSCT survivors who did not 
store sperm this was generally because they declined to do so (79%) or were too unwell to undergo 
the procedure (8%). Only 8 (5%) men, 2 of whom were under 40 years of age, were not offered 
sperm storage (Tables V and VI). 
 
Discussion 
 
While sexual dysfunction has previously been documented in HSCT survivors, most reports are from 
single centres and/or comprise small sample sizes. This study is the largest to date exploring sexual 
activity in survivors of allogeneic HSCT and the largest and most comprehensive study of fertility and 
sexuality in an Australian context. While the high response rate (76%) and use of validated 
instruments makes it likely that these results represent an accurate account of the experience of 
survivors of HSCT, the heterogeneity and restricted ethnic diversity in our population may limit the 
generalizability of these results to HSCT survivors in other countries and settings. The results from 
this research are also limited by the fact that it relied upon self-report and because no data is 
available about non-responders. Further, the instruments used in this study were ones that are 
widely used in HSCT settings to assess quality of life, physical and psychosocial function in HSCT 
survivors and were not specifically targeted at sexual function. 
 
This study demonstrates that the majority of HSCT survivors experience a wide range of sexual 
difficulties in the years following transplantation. Although most had resumed sexual activity, a 
significant proportion reported sexual difficulties (51% of males; 66% of females). Common to both 
genders were loss of libido and less enjoyment of sexual activity while 72% of women experienced 
pain with intercourse. These results are broadly consistent with other reports of sexual dysfunction 
after HSCT (Marks et al, 1997; Lee et al, 2002a; Tierney et al, 2007). As with other studies, age and 
cGVHD were significantly associated with sexual dysfunction post-HSCT (Heinonen et al, 2001; Lara 
et al, 2010; Mueller et al, 2013; Wong et al, 2013).  
 
While most patients generally resumed sexual activity post HSCT, consistent with other research, we 
found that this occurs most frequently and earlier in men than in women, and in younger HSCT 
survivors (Watson et al, 1999; Shanis et al, 2012). The association between cGVHD and the lack of 
return to sexual activity appeared to be more evident in males than females, with males who had 
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not resumed sexual activity following transplant reporting higher rates of immunosuppression, 
higher anti-infective drug use and higher self-reported cGVHD symptoms which is in keeping with 
previous studies (Lee et al, 2002a; Humphreys et al, 2007; Lara et al, 2010). Quality of life measures, 
especially those reflecting physical and functional well-being, were lower in males who had not 
returned to normal sexual activity and Lee cGVHD scores were signiﬁcantly higher in these survivors. 
 
Female HSCT survivors commonly report a range of genitourinary symptoms with significant vulvo-
vaginal cGVHD occurring in 221% of women who develop cGVHD post transplant. Genitourinary 
symptoms are more often reported in women who have resumed sexual activity however it is 
unclear if sexual activity exacerbated the problem, or if sexual activity allowed women to identify 
these problems (Spinelli et al, 2003; Zantomio et al, 2006; Stratton et al, 2007).  
 
As has been reported elsewhere, HSCT is invariably associated with premature ovarian failure and 
azoospermia; however, small numbers of survivors, particularly those aged under 30 years at the 
time of HSCT, may recover ovarian function/spermatogenesis and fertility (Sanders et al, 1988; Wang 
et al, 1998; Grigg et al, 2000; Salooja et al, 2001; Rovo et al, 2006; Jadoul et al, 2011; Wu et al, 2012). 
The majority of HSCT survivors are rendered infertile, however because the mean age at HSCT is 49 
years this may not constitute a significant concern for many HSCT survivors. While few HSCT 
survivors attempt to conceive post-transplant, many will be successful (43%), often with assisted 
reproductive technologies (Lipton et al, 1997; Demeestere et al, 2006; Donnez et al, 2011). 
Unfortunately such technologies are expensive and are located primarily in metropolitan areas – 
raising questions about equity of access. The challenges involved in conception post-HSCT underlie 
the importance of utilizing pre-HSCT fertility preservation measures, including sperm storage, 
ovarian tissue and/or oocyte or embryo storage (Lee et al, 2006; Wallace, 2011; Joshi et al, 2014). In 
this regard it was noteworthy that, in our population, a significant number of women rather than 
men (23% vs. 5% respectively) were not offered reproductive interventions. While this probably 
reflects practical difficulties associated with fertility preservation methods in women, it also 
highlights continuing uncertainty regarding the availability and efficacy of techniques for females. 
 
This study provides important insights into sexual dysfunction and infertility in an Australian cohort 
of HSCT survivors. Given the high prevalence of continued sexual dysfunction in the post-HSCT 
period (>66% for females, >50% for males), it is clear that pre-HSCT counselling and post-HSCT care 
needs to include full disclosure and assessment of the effects of transplant on sexual health and 
fertility, both for men and women, with greater attention paid to vaginal cGVHD than currently 
occurs. Consensus guidelines have recently been released with recommendations for regular, 
integrated gynaecological review both pre- and post-HSCT (Frey Tirri et al, 2015; Stratton, 2015). 
While such practice change seems undeniable, further work is required to establish whether other 
pre- and post-HSCT interventions, including education, counselling and early treatment, improves 
sexual function and quality of life outcomes for survivors. 
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Table 2. Demographic, social and clinical variables and their association with resumption 
of sexual activity post transplant, by Gender  
 Males Females 
 Resumed Sexual 
Activity post 
HSCT 
 
 
 
n=167 
Not resumed 
Sexual 
activity 
Post HSCT 
 
 
n=30 
P 
value 
Resumed 
Sexual Activity 
Post HSCT 
 
 
n=122 
Not resumed 
Sexual activity 
post HSCT 
 
 
n=21 
P 
value 
Socio-demographic factors 
Age in years  at 
survey  
(median; range) 
 
52 (21-79) 
 
58 (21-73) 
 
0.04 
 
49 (21-75) 
 
57(34-69) 
 
0.06 
Years since 
transplant 
(median,; range) 
 
5  (1-14) 
 
5   (1-14) 
 
0.32 
 
6   (1-14) 
 
3 (1-8) 
 
0.0009 
Relationship status  
Married/defacto 
Single,divorced, 
separated 
 
137/166(82.5%) 
29/168 (17.5%) 
 
22/30(73.3%) 
8/30(26.7%) 
 
0.31 
 
106/119 (89%) 
13/119 (11%) 
 
15/20 (75%) 
5 /20(25%) 
 
0.09 
Transplant factors 
Diagnosis 
Acute leukaemia 
Other diagnoses 
 
75 /140(53.6%) 
65/140 (53.6%) 
 
14/25 (56.0%) 
11/25(44.0%) 
 
0.82 
 
76/102(65.5%) 
40/102(35.5%) 
 
14/18(73.7%) 
4/18(26.3%) 
 
0.60 
Donor type 
Sibling 
Haploidentical      
Unrelated(matched) 
Unrelated 
(mismatched) 
 
89/166(53.6%) 
4 /166(2.4%) 
63/166(38.0%) 
10/166 (6.0%) 
 
16(53.3%) 
1 (3.3%) 
13(43.3%) 
0 
 
 
0.55 
 
74(60.7%) 
3 (2.5%) 
38(31.5%) 
7 (5.7%) 
 
12(57.1%) 
1 (4.8%) 
7 (33.3%) 
1 (4.8%) 
 
 
0.93 
Conditioning 
Myeloablative 
Reduced Intensity 
 
84 (50.9%) 
81(49.1%) 
 
11(36.7%) 
19(63.3%) 
 
0.15 
 
77(63.1%) 
45(36.9%) 
 
10(47.6%) 
11(52.4%) 
 
0.18 
 
Remission status  
CR1/CR2 
Other 
 
95(56.9%) 
72(43.1%) 
 
14(46.7%) 
16(53.3%) 
 
0.30 
 
87(71.3%) 
35(28.7%) 
 
17(81.0%) 
4 (19.0%) 
 
0.36 
Post-transplant factors 
Comorbidity 
Cardiovascular risk 
factors 
Bone disease  
Anxiety/depression 
Thyroid disease 
Iron overload 
 
69(43.7%) 
39(24.3%) 
48(28.7%) 
5(3.4%) 
53(35.6%) 
 
16(53.3%) 
11(36.7%) 
8(26.7%) 
2(7.1%) 
6(23.1%) 
 
0.13 
0.15 
0.82 
0.31 
0.26 
 
45(36.9%) 
41(33.6%) 
32(26.2%) 
7(5.7%) 
34(27.9%) 
 
6(28.6%) 
5(23.8%) 
1(4.8%) 
2(9.5%) 
6(28.6%) 
 
0.62 
0.45 
0.05 
0.62 
1.0 
Medical Therapy 
Immunosuppression 
Antiinfective 
 
65(38.9%) 
67(40.1%) 
 
19(63.3%) 
20(66.7%) 
 
0.01 
0.007 
 
26(21.3%) 
39(32.0%) 
 
5(23.8%) 
10(47.6%) 
 
0.78 
0.16 
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Psychotropic 
medication 
Hormone 
Replacement 
37(22.2%) 
12(7.2%) 
5(16.7%) 
0 
0.63 
0.22 
22(18.0%) 
41(33.6%) 
3(14.3%) 
5(23.8%) 
1.00 
0.45 
chronic GVHD 
Self-reported 
severity 
None  
Mild 
Moderate 
Severe 
Lee Chronic GVHD 
score   
Median (range) 
 
 
20/105(19.1%) 
55/105(52.4%) 
18/105 (17.1%) 
12/105 (11.4%) 
 
16 (0-77) 
 
 
1/19(5.3%) 
6/19(31.6%) 
7/19(36.8%) 
5/19(26.3%) 
 
30(5-54) 
 
 
 
0.03 
 
 
 
0.01 
 
 
15/77(19.5%) 
41/77(53.2%) 
18/77(23.4%) 
3/77(3.9%) 
 
15(0-61) 
 
 
1/12(8.3%) 
6/12(50.0%) 
4/12(33.3%) 
1/12(8.3%) 
 
20(6-47) 
 
 
 
0.66 
 
 
 
0.40 
 
 
 
Table 3. Quality of life measures (FACT), post traumatic growth inventory measures,  and 
resumption of sexual activity post transplant, by Gender 
 Males Females 
 Resumed Sexual 
Activity post 
HSCT 
 
 
Not resumed 
Sexual activity 
Post HSCT 
 
P 
value 
Resumed 
Sexual 
Activity 
Post HSCT 
 
 
Not resumed 
Sexual activity 
post HSCT 
 
P 
value 
FACT scores 
(median, range) 
FACT- physical 
FACT- social 
FACT-emotional 
FACT-functional 
FACT-HSCT 
subscale 
FACT -G 
FACT HSCT Total 
 
24 (0-28) 
21(4-28) 
17(1-24) 
21(4-28) 
30(9-40) 
82(22-104) 
113(32-144) 
 
19 (5-28) 
22(1-27) 
17(7-20) 
16 (0-28) 
26(7-38) 
70(40-95) 
94(52-129) 
 
0.01 
0.92 
0.66 
0.009 
0.003 
0.03 
0.01 
 
 
 
25(0-28) 
22(7-28) 
16(0-20) 
21(5-28) 
29(11-40) 
83(36-104) 
111(49-141) 
 
24(12-28) 
21(14-28) 
17(0-20) 
19(8-28) 
26(18-32) 
81(61-103) 
109(80-134) 
 
0.34 
0.70 
0.77 
0.21 
0.02 
0.58 
0.23 
Post Traumatic 
Growth 
Inventory 
median, range 
 
54 (0-96) 
 
54(16-79) 
 
0.74 
 
63(12-103) 
 
53(18-93) 
 
0.35 
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Table 4: Sexual dysfunction reported by males and females who had resumed sexual 
activity post transplant  
Type of sexual 
dyssfunction 
Sexual dysfunction  following 
resumption sexual activity 
(Females) 
Total=81 
 
Sexual dysfunction  
following resumption 
sexual activity 
(Males) 
Total=86 
 
Odds ratio 
(95% CI) 
 
 
P value 
Decreased 
enjoyment of sex 
 
 
55/81 (67.9%)  
 
28/86(32.6%) 
  
4.3 ( 2.2, 8.8) 
 
 
<0.0001 
Pain with 
intercourse 
 
59/81 (72.8%) 
 
8/86 (9.3%) 
 
26.1(10.2, 
71.3) 
 
<0.0001 
Decreased sexual 
desire 
 
67/81 (82.7%) 
 
53/86(61.6%) 
  
3.0 (1.4, 6.6) 
 
 
0.002 
Difficulties with 
arousal/erection 
 
47/81 (58%) 
 
N/A 
Not 
comparable 
to males 
 
- 
Difficulties with 
erection 
 
N/A 
 
66 /86 (76.7%) 
Not 
comparable 
to females 
 
- 
Difficulties with 
partner regarding 
issue of sex 
 
27/81 (33.3%) 
 
28/86 (32.6%) 
 
1.03 (0.5, 
2.1) 
 
0.91 
Other  Other difficulties described by females 
included vaginal 
bleeding/dryness/GVHD(11) 
mobility/flexibility issues (1) post gynae 
surgery problems (1) body confidence (1) 
low libido (1) partner issues(1) 
 
Other difficulties described by 
males included  recurrent 
hospitalizations (1), neurological 
damage to penis following 
episode of shingles (1), reduced 
muscular strength & joint pains  
and breathing difficulties (3) 
 
  
 
 
 
Table 5: Reasons given for females who did not use medically assisted reproductive 
methods pre-transplant by age.  
Age range (years) 18-29 
n=19 
30-39 
n=30 
40-49 
n=26 
50-59 
n=47 
60-69 
n=21 
>=70 
n=1 
All 
N=144 
Not offered (n=19) 1 (5.3%) 7 (23%) 4 
(15.4%) 
2 
(4.3%) 
0 0 14/144 
(9.7%) 
Declined 1 (5.3%) 12 
(40%) 
18 
(69.2%) 
44 (93.6%) 20 0 95/144 
(66%) 
Too sick or other health 
problems 
5 (26.3%) 2 
(6.7%) 
3 
(11.5%) 
1 (2.1%) 0 0 11/144 
(7.6%) 
Completed family 12 (63.1%) 9 (30%) 1 (3.8%) 0 1 1 24/144 
(16%) 
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Table 6: Reasons given for males who did not use medically assisted reproductive 
methods pre-transplant by age. 
Age range (years) 18-29 
n=7 
30-39 
n=16 
40-49 
n=43 
50-59 
n=63 
60-69 
n=28 
>=70 
n=1 
All 
N=156 
Not offered (n=19) 1  1  2 
 
3 
 
1 0 8/156 
(5.1%) 
Declined 0 8 34 54 27 1 124/156 
(79.5%) 
Too sick or other health problems 1 4 5 2 0 0 12/156 
(7.7%) 
Completed family 3 3 2 4 0 0 12/156 
(7.7%) 
 
